G71.034

Clinical Causes: Genetic mutations affecting sarcoglycan proteins, part of the dystrophin-glycoprotein complex in muscle fibers. Inheritance patterns primarily include autosomal recessive traits, meaning a person inherits two copies of the mutated gene—one from each parent. Mutations in genes such as SGCA, SGCB, SGCG, or SGCD, which encode different sarcoglycan proteins, can lead to this form of LGMD.

Key Symptoms: Progressive weakness in shoulder and hip muscles, leading to difficulty with activities like lifting, climbing stairs, or rising from a seated position. Muscle wasting or atrophy, often more pronounced in the proximal muscles (closer to the trunk). Potential development of contractures or joint stiffness over time. In some cases, there may be cardiac or respiratory complications if the condition affects heart or diaphragm muscles. Fatigue and reduced exercise tolerance are common as muscle strength declines.

Diagnosis Path: Diagnosing this form of LGMD involves a combination of clinical assessments and specialized tests: - Detailed medical and family history to identify inherited patterns. - Physical examination focusing on muscle strength and tone. - Electromyography (EMG) to analyze electrical activity in muscles. - Blood tests measuring levels of muscle enzymes such as creatine kinase (CK), which may be elevated. - Muscle biopsy to examine muscle tissue under a microscope for characteristic changes. - Genetic testing to identify mutations in specific sarcoglycan genes, confirming the diagnosis. - Imaging techniques like MRI can assist in evaluating muscle involvement and progression.

Treatment Protocols: Currently, there is no cure for limb-girdle muscular dystrophy due to sarcoglycan dysfunction. Management strategies aim to improve quality of life and maintain muscle function: - Physical therapy to promote mobility, prevent contractures, and strengthen unaffected muscles. - Occupational therapy to assist with daily activities. - Use of assistive devices such as braces, canes, or wheelchairs as mobility declines. - Respiratory support if respiratory muscles are affected. - Regular cardiac monitoring and treatment if heart symptoms emerge. - Medications like corticosteroids may be considered in some cases to slow disease progression. - Participation in clinical trials exploring new therapies might be an option for some patients.